In conclusion, our findings first demonstrate that miR-27a-3p is a prognostic and/or potential therapeutic biomarker for CRC patients and RXRα as miR-27a-3p targeting gene plays the critical role in activation of Wnt/β-catenin pathway during CRC progression. This evidence concerns the gene RXRA and colorectal carcinoma.